Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.

Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, Tang B, Guo J.

Eur J Cancer. 2011 Jul;47(10):1498-503. doi: 10.1016/j.ejca.2011.03.019. Epub 2011 Apr 13.

PMID:
21493058
2.

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.

Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group.

Lancet Oncol. 2011 Feb;12(2):144-52. doi: 10.1016/S1470-2045(10)70288-6. Epub 2011 Jan 20.

PMID:
21256809
3.

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M.

J Clin Oncol. 2004 Jan 1;22(1):53-61. Epub 2003 Dec 9.

PMID:
14665609
4.

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.

Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, Kalofonos H, Fountzilas G, Panagiotou P, Kokkalis G, Papadopoulos O, Castana O, Papadopoulos S, Stavrinidis E, Vourli G, Ioannovich J, Gogas H.

J Clin Oncol. 2009 Feb 20;27(6):939-44. doi: 10.1200/JCO.2008.16.3121. Epub 2009 Jan 12.

PMID:
19139440
5.

Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.

Muggiano A, Mulas C, Fiori B, Liciardi G, Pintus M, Tanca L, Tedde A, Turno R, Desogus A.

Melanoma Res. 2004 Apr;14(2):S1-7.

PMID:
15057049
6.

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.

Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE.

J Clin Oncol. 2007 May 20;25(15):2078-85.

PMID:
17513813
7.

Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.

Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group.

Eur J Cancer. 2016 Mar;55:111-21. doi: 10.1016/j.ejca.2015.11.014. Epub 2016 Jan 17.

PMID:
26790144
8.

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

Mocellin S, Pasquali S, Rossi CR, Nitti D.

J Natl Cancer Inst. 2010 Apr 7;102(7):493-501. doi: 10.1093/jnci/djq009. Epub 2010 Feb 23. Review.

PMID:
20179267
9.

Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.

Ascierto PA, Daponte A, Parasole R, Perrone F, Caracò C, Melucci M, Palmieri G, Napolitano M, Mozzillo N, Castello G.

Cancer. 2000 Oct 1;89(7):1490-4.

PMID:
11013362
11.

[Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].

Bédane C, Le Brun V, Boulinguez S, Berdah JF, Bouyssou ML, Delpuget N, Bernard P, Tubiana-Mathieu N, Bonnetblanc JM.

Ann Dermatol Venereol. 1999 Feb;126(2):142-6. French.

12.

Adjuvant irradiation for axillary metastases from malignant melanoma.

Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE, Ross MI.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):964-72.

PMID:
11958890
14.

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.

Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L.

J Am Coll Surg. 1998 Jul;187(1):69-77; discussion 77-9.

PMID:
9660028
15.

The role of adjuvant therapy in melanoma management.

Barth A, Morton DL.

Cancer. 1995 Jan 15;75(2 Suppl):726-34. Review.

16.

A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.

Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY.

Melanoma Res. 2009 Feb;19(1):42-9. doi: 10.1097/CMR.0b013e328314b84a.

PMID:
19430405
17.

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH.

J Clin Oncol. 2000 Jun;18(12):2444-58.

PMID:
10856105
18.

Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials.

Malczewski A, Marshall A, Payne MJ, Mao L, Bafaloukos D, Si L, Pectasides D, Fountzilas G, Guo J, Gogas H, Middleton MR.

Cancer Med. 2016 Jan;5(1):17-23. doi: 10.1002/cam4.563. Epub 2015 Dec 8.

19.

Patterns of failure after induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma: the Queen Mary Hospital experience.

Chua DT, Sham JS, Choy D, Kwong DL, Au GK, Kwong PW, Yau CC, Cheng AC, Wan KY.

Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1219-28.

PMID:
11286826
20.

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH.

J Clin Oncol. 1996 Jan;14(1):7-17.

PMID:
8558223

Supplemental Content

Support Center